Valmark Advisers Inc. Decreases Position in Danaher Co. (NYSE:DHR)

Valmark Advisers Inc. trimmed its position in Danaher Co. (NYSE:DHR) by 37.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,871 shares of the conglomerate’s stock after selling 1,099 shares during the period. Valmark Advisers Inc.’s holdings in Danaher were worth $433,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Nicholas Hoffman & Company LLC. increased its position in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after acquiring an additional 43 shares during the period. Drive Wealth Management LLC increased its position in shares of Danaher by 3.1% in the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after acquiring an additional 44 shares during the period. Trust Investment Advisors increased its position in shares of Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after acquiring an additional 49 shares during the period. Connolly Sarah T. increased its position in shares of Danaher by 0.5% in the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock valued at $2,382,000 after acquiring an additional 50 shares during the period. Finally, Austin Private Wealth LLC increased its position in shares of Danaher by 3.4% in the 3rd quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock valued at $389,000 after acquiring an additional 51 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on DHR. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Barclays increased their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. Citigroup increased their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $269.64.

Danaher Trading Up 0.3 %

DHR stock opened at $246.58 on Monday. The company’s 50-day simple moving average is $248.87 and its 200-day simple moving average is $231.27. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The firm has a market cap of $182.64 billion, a P/E ratio of 41.79, a PEG ratio of 3.80 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period last year, the company posted $2.36 EPS. As a group, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a $0.27 dividend. The ex-dividend date was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,565 shares of company stock valued at $26,641,364. 10.90% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.